However, the participants in our study had decreased HbA1c by 0.11%, which is thought to be less effective in reducing HbA1c by using SGLT2 inhibitors in overweight or obese patients with poor control of T2DM. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.